{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Antimalarial drugs", "HEV", "Hepatitis E", "In vitro screening", "Virtual screening"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "33959472", "DateRevised": {"Year": "2023", "Month": "11", "Day": "11"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "05", "Day": "04"}], "Language": ["eng"], "ELocationID": ["35", "10.1007/s40203-021-00093-y"], "Journal": {"ISSN": "2193-9616", "JournalIssue": {"Volume": "9", "Issue": "1", "PubDate": {"Year": "2021"}}, "Title": "In silico pharmacology", "ISOAbbreviation": "In Silico Pharmacol"}, "ArticleTitle": "In silico and in vitro screening of licensed antimalarial drugs for repurposing as inhibitors of hepatitis E virus.", "Pagination": {"StartPage": "35", "MedlinePgn": "35"}, "Abstract": {"AbstractText": ["Hepatitis E virus (HEV) infection is emerging in Cameroon and represents one of the most common causes of acute hepatitis and jaundice. Moreover, earlier reports showed evidence of falciparum malaria/HEVcoexistence. Although the Sofosbuvir/Ribavirin combination was recently proposed in the treatment of HEV-infected patients, no specific antiviral drug has been approved so far, thereby urging the search for new therapies. Fortunately, drug repurposing offers a good alternative to this end. In this study, we report the in silico and in vitro activities of 8 licensed antimalarial drugs and two anti-hepatitis C virus agents used as references (Sofosbuvir, and Ribavirin), for repurposing as antiviral inhibitors against HEV. Compounds were docked against five HEV-specific targets including the Zinc-binding non-structural protein (6NU9), RNA-dependent RNA polymerase (RdRp), cryoEM structure of HEV VLP, genotype 1 (6LAT), capsid protein ORF-2, genotype 3 (2ZTN), and the E2s domain of genotype 1 (3GGQ) using the iGEMDOCK software and their pharmacokinetic profiles and toxicities were predicted using ADMETlab2.0. Their in vitro effects were also assessed on a gt 3 p6Gluc replicon system using the luciferase reporter assay. The docking results showed that Sofosbuvir had the best binding affinities with 6NU9 (-\u00a098.22\u00a0kcal/mol), RdRp (-\u00a0113.86\u00a0kcal/mol), 2ZTN (-\u00a0106.96\u00a0kcal/mol), while Ribavirin better collided with 6LAT (-\u00a099.33\u00a0kcal/mol). Interestingly, Lumefantrine showed the best affinity with 3GGQ (-106.05\u00a0kcal/mol). <i>N</i>-desethylamodiaquine and Amodiaquine presented higher binding scores with 6NU9 (-\u00a093.5 and -\u00a089.9\u00a0kcal/mol respectively vs -\u00a080.83\u00a0kcal/mol), while Lumefantrine had the greatest energies with RdRp (-\u00a0102 vs -\u00a084.58), and Pyrimethamine and <i>N</i>-desethylamodiaquine had stronger affinities with 2ZTN compared to Ribavirin (-\u00a0105.17 and -\u00a0102.65\u00a0kcal/mol vs -\u00a096.04\u00a0kcal/mol). The biological screening demonstrated a significant (<i>P</i>\u2009<\u20090.001) antiviral effect on replication with 1\u00a0\u00b5M\u00a0N-desethylamodiaquine, the major metabolite of Amodiaquine. However, Lumefantrine showed no effect at the tested concentrations (1, 5, and 10\u00a0\u00b5M). The biocomputational analysis of the pharmacokinetic profile of both drugs revealed a low permeability of Lumefantrine and a specific inactivation by CYP3A2 which might partly contribute to the short half-time of this drug. In conclusion, Amodiaquine and Lumefantrine may be good antimalarial drug candidates for repurposing against HEV. Further in vitro and in vivo experiments are necessary to validate these predictions.", "The online version contains supplementary material available at 10.1007/s40203-021-00093-y."], "CopyrightInformation": "\u00a9 The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021."}, "AuthorList": [{"Identifier": ["0000-0002-4324-5951"], "AffiliationInfo": [{"Identifier": ["grid.440604.2", "0000 0000 9169 7229"], "Affiliation": "Laboratory of Applied Biochemistry, Department of Biological Sciences, Faculty of Science, University of Ngaoundere, P.O. Box 454, Ngaoundere, Cameroon."}, {"Identifier": ["grid.412661.6", "0000 0001 2173 8504"], "Affiliation": "Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty ofScience, University of Yaounde I, P.O. Box 812, Yaounde, Cameroon."}], "LastName": "Tietcheu Galani", "ForeName": "Borris Rosnay", "Initials": "BR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": ["grid.412661.6", "0000 0001 2173 8504"], "Affiliation": "Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty ofScience, University of Yaounde I, P.O. Box 812, Yaounde, Cameroon."}], "LastName": "Ayissi Owona", "ForeName": "Vincent Brice", "Initials": "VB"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": ["grid.440604.2", "0000 0000 9169 7229"], "Affiliation": "Laboratory of Medicinal Plants, Health, and Galenic Formulation, Department of Biological Sciences, Faculty of Science, University of Ngaoundere, P.O. Box 454, Ngaoundere, Cameroon."}], "LastName": "Guemmogne Temdie", "ForeName": "Romeo Joel", "Initials": "RJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": ["grid.503422.2", "0000 0001 2242 6780"], "Affiliation": "University of Lille, CNRS, INSERM, CHU Lille, Pasteur Institute of Lille, U1019-UMR9017-CIIL-Center for Infection and Immunity of Lille, 59000 Lille, France."}], "LastName": "Metzger", "ForeName": "Karoline", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": ["grid.412661.6", "0000 0001 2173 8504"], "Affiliation": "Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty ofScience, University of Yaounde I, P.O. Box 812, Yaounde, Cameroon."}, {"Identifier": [], "Affiliation": "Research Center for Emerging and Reemerging Infectious Diseases (CREMER-IMPM), Virology Unit, P.O. Box 906, Yaounde, Cameroon."}], "LastName": "Atsama Amougou", "ForeName": "Marie", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": ["grid.449595.0", "0000 0004 0578 4721"], "Affiliation": "Department of Medicine, Medical and Biomedical Sciences, Higher Institute of Health Sciences, Universit\u00e9 Des Montagnes, P.O. Box 208, Bangangte, Cameroon."}], "LastName": "Djamen Chuisseu", "ForeName": "Pascal Dieudonn\u00e9", "Initials": "PD"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": ["grid.412661.6", "0000 0001 2173 8504"], "Affiliation": "Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty ofScience, University of Yaounde I, P.O. Box 812, Yaounde, Cameroon."}, {"Identifier": ["grid.29273.3d", "0000 0001 2288 3199"], "Affiliation": "Department of Biomedical Sciences, Faculty of Health Sciences, University of Buea, P.O Box 63, Buea, South West Region Cameroon."}], "LastName": "Fondjo Kouam", "ForeName": "Arnaud", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": ["grid.412661.6", "0000 0001 2173 8504"], "Affiliation": "Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty ofScience, University of Yaounde I, P.O. Box 812, Yaounde, Cameroon."}], "LastName": "Ngounoue Djuidje", "ForeName": "Marceline", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": ["grid.503422.2", "0000 0001 2242 6780"], "Affiliation": "University of Lille, CNRS, INSERM, CHU Lille, Pasteur Institute of Lille, U1019-UMR9017-CIIL-Center for Infection and Immunity of Lille, 59000 Lille, France."}], "LastName": "Aliouat-Denis", "ForeName": "C\u00e9cile-Marie", "Initials": "CM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": ["grid.503422.2", "0000 0001 2242 6780"], "Affiliation": "University of Lille, CNRS, INSERM, CHU Lille, Pasteur Institute of Lille, U1019-UMR9017-CIIL-Center for Infection and Immunity of Lille, 59000 Lille, France."}], "LastName": "Cocquerel", "ForeName": "Laurence", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": ["grid.412661.6", "0000 0001 2173 8504"], "Affiliation": "Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty ofScience, University of Yaounde I, P.O. Box 812, Yaounde, Cameroon."}], "LastName": "Fewou Moundipa", "ForeName": "Paul", "Initials": "P"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "In Silico Pharmacol", "NlmUniqueID": "101623954", "ISSNLinking": "2193-9616"}, "CoiStatement": "Conflict of interestThe authors have no conflict of interest to disclose for this manuscript."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Amougou AM, Atangana PJA, Noah Noah D, Moundipa PF, Pineau P, Njouom R (2007) Hepatitis E virus infection as a promoting factor for hepatocellular carcinoma in Cameroon: preliminary Observations. Int J Infect Dis [Internet] Elsevier BV 64:4\u20138 Available at https://pubmed.ncbi.nlm.nih.gov/28847760/ [cited 2020 Oct 12]", "ArticleIdList": ["28847760"]}, {"Citation": "Aslam SM. Case study an interesting case of complicated falciparum malaria and hepatitis E virus co-infection. Int J Clin Cases Investig. 2017;6(3):35\u201337."}, {"Citation": "Bai C, Cai J, Han P, Qi J, Yuen KY, Wang Q (2020) The crystal structure of the emerging human-infecting hepatitis E virus E2s protein. Biochem Biophys Res Commun [Internet]. Elsevier Ltd 532(1):25\u201331 10.1016/j.bbrc.2020.07.074", "ArticleIdList": ["32819713"]}, {"Citation": "Barger-Kamate B, Forman M, Sangare CO, Haidara ASA, Maiga H, Vaidya D, et al (2016) Effect of artemether-lumefantrine (Coartem) on cytomegalovirus urine viral load during and following treatment for malaria in children. J Clin Virol [Internet]. Elsevier BV 77:40\u20135 Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792724/ [cited 2020 Oct 20]", "ArticleIdList": ["PMC4792724", "26895228"]}, {"Citation": "Boonyasuppayakorn S, Reichert ED, Manzano M, Nagarajan K, Padmanabhan R (2014) Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity. Antiviral Res Elsevier 106(1):125\u2013134. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4523242/ [cited 2020 Oct 15]", "ArticleIdList": ["PMC4523242", "24680954"]}, {"Citation": "Dao Thi VL, Debing Y, Wu X, Rice CM, Neyts J, Moradpour D, et al (2016) Sofosbuvir inhibits hepatitis e virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology 150(1):82\u201385.e4. 10.1053/j.gastro.2015.09.011", "ArticleIdList": ["26408347"]}, {"Citation": "Doceul V, Bagdassarian E, Demange A, Pavio N. Zoonotic HEPATITIS E virus: classification, animal reservoirs and transmission routes. Viruses. 2016;8(10):1\u201324. doi: 10.3390/v8100270.", "ArticleIdList": ["10.3390/v8100270", "PMC5086606", "27706110"]}, {"Citation": "Dong J, Wang N-N, Yao Z-J, Zhang L, Cheng Y, Ouyang D, et al (2018) ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. J Cheminform 10(1):29. Available at: https://jcheminf.biomedcentral.com/articles/10.1186/s13321-018-0283-x [cited 2021 Mar 29]", "ArticleIdList": ["10.1186/s13321-018-0283-x", "PMC6020094", "29943074"]}, {"Citation": "Donnelly MC, Scobie L, Crossan CL, Dalton H, Hayes PC, Simpson KJ. Review article: hepatitis E\u2014a concise review of virology, epidemiology, clinical presentation and therapy. Aliment Pharmacol Ther. 2017;46(2):126\u2013141. doi: 10.1111/apt.14109.", "ArticleIdList": ["10.1111/apt.14109", "28449246"]}, {"Citation": "Emerson SU, Nguyen HT, Torian U, Mather K, Firth AE. An essential RNA element resides in a central region of hepatitis E virus ORF2. J Gen Virol 94(PART7):1468\u201376. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709636/ [cited 2021 Mar 28]", "ArticleIdList": ["PMC3709636", "23515023"]}, {"Citation": "Fraga M, Gouttenoire J, Sahli R, Chtioui H, Marcu C, Pascual M, et al (2019) Sofosbuvir add-on to ribavirin for chronic hepatitis e in a cirrhotic liver transplant recipient: a case report. BMC Gastroenterol 19(1):76. Available at https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-019-0995-z [cited 2020 Oct 13];", "ArticleIdList": ["10.1186/s12876-019-0995-z", "PMC6534895", "31126238"]}, {"Citation": "Gouttenoire J, Poll\u00e1n A, Abrami L, Oechslin N, Mauron J, Matter M, et al. Palmitoylation mediates membrane association of hepatitis E virus ORF3 protein and is required for infectious particle secretion. PLoS Pathog 14(12). Available at https://pubmed.ncbi.nlm.nih.gov/30532200/ [cited 2020 Oct 23]", "ArticleIdList": ["PMC6307819", "30532200"]}, {"Citation": "Gu Y, Tang X, Zhang X, Song C, Zheng M, Wang K, et al. Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody. Cell Res Nature Publishing Group 25(5):604\u2013620. Available at https://www.nature.com/articles/cr201534 [cited 2020 Oct 16]", "ArticleIdList": ["PMC4423075", "25793314"]}, {"Citation": "Guex N, Peitsch MC, Schwede T. Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective. Electrophoresis. 2009;30:S162\u2013S173. doi: 10.1002/elps.200900140.", "ArticleIdList": ["10.1002/elps.200900140", "19517507"]}, {"Citation": "Guu T, Liu Z, Ye Q, Mata D, Li K, Yin C, et al. Structure of the hepatitis E virus-like particle suggests mechanisms for virus assembly and receptor binding. Proc Natl Acad Sci USA. 2009;106:12992\u201312997. doi: 10.1073/pnas.0904848106.", "ArticleIdList": ["10.1073/pnas.0904848106", "PMC2722310", "19622744"]}, {"Citation": "Han Y, Mespl\u00e8de T, Xu H, Quan Y, Wainberg MA. The antimalarial drug amodiaquine possesses anti\u2010ZIKA virus activities. J Med Virol John Wiley and Sons Inc 90(5):796\u2013802. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25031 [cited 2020 Oct 15]", "ArticleIdList": ["10.1002/jmv.25031", "29315671"]}, {"Citation": "He S, Miao J, Zheng Z, Wu T, Xie M, Tang M, et al. Putative receptor-binding sites of hepatitis E virus. J Gen Virol Microbiology Soc 89(1):245\u2013249. Available at: https://www.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.83308-0 [cited 2020 Oct 16]", "ArticleIdList": ["10.1099/vir.0.83308-0", "18089748"]}, {"Citation": "Kenney SP, Meng XJ. Hepatitis E virus genome structure and replication strategy. Cold Spring Harb Perspect Med. 2019;9(1):1\u201318. doi: 10.1101/cshperspect.a031724.", "ArticleIdList": ["10.1101/cshperspect.a031724", "PMC6314074", "29530948"]}, {"Citation": "Kinast V, Burkard TL, Todt D, Steinmann E. Hepatitis E virus drug development. Viruses. 2019;11(6):1\u201316. doi: 10.3390/v11060485.", "ArticleIdList": ["10.3390/v11060485", "PMC6631701", "31141919"]}, {"Citation": "Liu Z, Jane Y, Zhang J (2011) Structure and function of the hepatitis E virus capsid related to hepatitis E pathogenesis. In: Mukomolov DS, editor. Viral Hepat\u2014Sel. Issues Pathog. Diagnostics [Internet]. In Tech; 2011. p. 141\u2013152. Available at http://www.intechopen.com/books/viral-hepatitis-selected-issues-of-pathogenesis-and-diagnostics/structure-and-function-of-the-hepatitis-e-virus-capsid-related-to-hepatitis-e-pathogenesis"}, {"Citation": "Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet Lancet Publishing Group 380(9859):2095\u2013128. Available at: https://pubmed.ncbi.nlm.nih.gov/23245604/ [cited 2020 Oct 12]", "ArticleIdList": ["PMC10790329", "23245604"]}, {"Citation": "Mirdita M, von den Driesch L, Galiez C, Martin MJ, S\u00f6ding J, Steinegger M. Uniclust databases of clustered and deeply annotated protein sequences and alignments. Nucleic Acids Res. 2016;45:D170\u2013D176. doi: 10.1093/nar/gkw1081.", "ArticleIdList": ["10.1093/nar/gkw1081", "PMC5614098", "27899574"]}, {"Citation": "Modiyinji AF, Atsama MA, Monamele GC, Nola M, Njouom R. High seroprevalence of hepatitis e among pigs suggests an animal reservoir in Cameroon. J Infect Dev Ctries [Internet] 12(8):676\u2013679. Available at https://jidc.org/index.php/journal/article/view/10310 [cited 2020 Oct 13]", "ArticleIdList": ["31958332"]}, {"Citation": "Modiyinji AF, Amougou-Atsama M, Monamele CG, Nola M, Njouom R (2019) Seroprevalence of hepatitis E virus antibodies in different human populations of Cameroon. J Med Virol John Wiley and Sons Inc. 91(11):1989\u201394. Available at: https://pubmed.ncbi.nlm.nih.gov/31297845/ [cited 2020 Oct 12]", "ArticleIdList": ["31297845"]}, {"Citation": "Modiyinji AF, Rivero\u2010Juarez A, Lopez\u2010Lopez P, Atsama MA, Monamele CG, Nola M, et al (2020) First molecular characterization of the hepatitis E virus in humans in Cameroon: confirmation of the HEV outbreak in Touboro, North\u2010Cameroon. J Med Virol. Available at: https://pubmed.ncbi.nlm.nih.gov/32639604/ [cited 2020 Oct 12]", "ArticleIdList": ["32639604"]}, {"Citation": "Montpellier C, Wychowski C, Sayed IM, Meunier JC, Saliou JM, Ankavay M, et al (2018) Hepatitis E virus lifecycle and identification of 3 forms of the ORF2 capsid protein. Gastroenterology [Internet] WB Saunders 154(1):211\u2013223.e8. Available at: http://www.gastrojournal.org/article/S0016508517361796/fulltext [cited 2021 Mar 28]", "ArticleIdList": ["28958858"]}, {"Citation": "Nair VP, Anang S, Subramani C, Madhvi A, Bakshi K, Srivastava A, et al (2016) Endoplasmic reticulum stress induced synthesis of a novel viral factor mediates efficient replication of genotype-1 hepatitis E virus. PLoS Pathog [Internet] Public Library of Science12(4). Available at https://pubmed.ncbi.nlm.nih.gov/27035822/ [cited 2020 Oct 13]", "ArticleIdList": ["PMC4817972", "27035822"]}, {"Citation": "Nan Y, Wu C, Zhao Q, Sun Y, Zhang YJ, Zhou EM (2018) Vaccine development against zoonotic hepatitis E virus: open questions and remaining challenges [Internet]. Front Microbiol Front Media SA. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827553/ [cited 2020 Oct 23]", "ArticleIdList": ["PMC5827553", "29520257"]}, {"Citation": "Navaneethan U, Al Mohajer M, Shata MT (2018) Hepatitis E and pregnancy: Understanding the pathogenesis [Internet]. Liver Int NIH Public Access\u00a0: 1190\u20131199. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575020/ [cited 2020 Oct 12].", "ArticleIdList": ["PMC2575020", "18662274"]}, {"Citation": "Nimgaonkar I, Ding Q, Schwartz RE, Ploss A (2018) Hepatitis E virus: advances and challenges. Nat Rev Gastroenterol Hepatol [Internet] Nature Publishing Group 15(2):96\u2013110. Available at http://www.nature.com/articles/nrgastro.2017.150 [cited 2020 Oct 23]", "ArticleIdList": ["29162935"]}, {"Citation": "Nitta S, Asahina Y, Matsuda M, Yamada N, Sugiyama R, Masaki T, et al. Effects of resistance-associated NS5A mutations in hepatitis C virus on viral production and susceptibility to antiviral reagents. Sci Rep [Internet] Nature Publishing Group 6(1):1\u20139. Available at: www.nature.com/scientificreports [cited 2021 Mar 28]", "ArticleIdList": ["PMC5050404", "27703205"]}, {"Citation": "Passini E, Britton OJ, Lu HR, Rohrbacher J, Hermans AN, Gallacher DJ, et al. Human in silico drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity. Front Physiol 8(SEP):1\u201315.", "ArticleIdList": ["PMC5601077", "28955244"]}, {"Citation": "Proudfoot A, Hyrina A, Holdorf M, Frank AO, Bussiere D (2019) First crystal structure of a nonstructural hepatitis e viral protein identifies a putative novel zinc-binding protein. J Virol American Society for Microbiology 93(13). Available at: https://pubmed.ncbi.nlm.nih.gov/31019049/ [cited 2020 Oct 14]", "ArticleIdList": ["PMC6580954", "31019049"]}, {"Citation": "Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST (2012) The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology [Internet] 55(4):988\u201397. Available at: https://pubmed.ncbi.nlm.nih.gov/22121109/ [cited 2020 Oct 12]", "ArticleIdList": ["22121109"]}, {"Citation": "Sachdeva C, Wadhwa A, Kumari A, Hussain F, Jha P, Kaushik NK. In silico potential of approved antimalarial drugs for repurposing against COVID-19. Omi A J Integr Biol. 2020;24(10):568\u2013581. doi: 10.1089/omi.2020.0071.", "ArticleIdList": ["10.1089/omi.2020.0071", "32757981"]}, {"Citation": "Schofield DJ, Purcell RH, Nguyen HT, Emerson SU. Monoclonal antibodies that neutralize HEV recognize an antigenic site at the carboxyterminus of an ORF2 protein vaccine. Vaccine. 2003;22(2):257\u2013267. doi: 10.1016/j.vaccine.2003.07.008.", "ArticleIdList": ["10.1016/j.vaccine.2003.07.008", "14615154"]}, {"Citation": "Shukla J, Saxena D, Rathinam S, Lalitha P, Joseph CR, Sharma S, et al (2012) Molecular detection and characterization of West Nile virus associated with multifocal retinitis in patients from southern India. Int J Infect Dis [Internet]. Elsevier 16(1):e53\u20139. Available at: http://www.ijidonline.com/article/S120197121100213X/fulltext [cited 2021 Mar 28]", "ArticleIdList": ["22099888"]}, {"Citation": "Smith SA, Waters NJ (2019) Pharmacokinetic and pharmacodynamic considerations for drugs binding to alpha-1-acid glycoprotein [Internet]. Pharm Res Springer New York LLC\u00a0: 30. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089466/", "ArticleIdList": ["PMC7089466", "30593605"]}, {"Citation": "Smith DB, Simmonds P, Jameel S, Emerson SU, Harrison TJ, Meng XJ, et al (2014) Consensus proposals for classification of the family Hepeviridae. J Gen Virol", "ArticleIdList": ["PMC4165930", "24989172"]}, {"Citation": "Steinegger M, Meier M, Mirdita M, V\u00f6hringer H, Haunsberger SJ, S\u00f6ding J (2019) HH-suite3 for fast remote homology detection and deep protein annotation. BMC Bioinform 20(473).", "ArticleIdList": ["PMC6744700", "31521110"]}, {"Citation": "Studer G, Rempfer C, Waterhouse AM, Gumienny G, Haas J, Schwede T. QMEANDisCo\u2014distance constraints applied on model quality estimation. Bioinformatics. 2020;36:1765\u20131771. doi: 10.1093/bioinformatics/btz828.", "ArticleIdList": ["10.1093/bioinformatics/btz828", "PMC7075525", "31697312"]}, {"Citation": "Tang X, Yang C, Gu Y, Song C, Zhang X, Wang Y, et al (2011) Structural basis for the neutralization and genotype specificity of hepatitis E virus. Proc Natl Acad Sci USA. [Internet]. National Academy of Sciences 108(25):10266\u201371. Available at: /pmc/articles/PMC3121834/?report=abstract [cited 2020 Oct 16]", "ArticleIdList": ["PMC3121834", "21642534"]}, {"Citation": "Thi DVL, Debing Y, Wu X, Rice CM, Neyts J, Moradpour D, et al (2016) Sofosbuvir inhibits hepatitis e virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology [Internet]. Elsevier, Inc 150(1):82\u201385.e4. 10.1053/j.gastro.2015.09.011", "ArticleIdList": ["26408347"]}, {"Citation": "Turner J, Ch\u2019ng CL. Acute hepatitis E with coexistent plasmodium falciparum infection in a patient with a history of foreign travel. Am J Case Rep. 2008;9:252\u20134."}, {"Citation": "WHO (2020) Hepatitis E: key facts [Internet]. Available at https://www.who.int/news-room/fact-sheets/detail/hepatitis-e"}, {"Citation": "Wilson A, Ndam N, Nsangou O, Njoya M, Njouom R, Kowo M, et al. Seroprevalence of HEPATITIS E virus infection and factors associated in HIV infected patients in Yaound\u00e9 (Cameroon) Open J Gastroenterol. 2020;10:181\u2013186. doi: 10.4236/ojgas.2020.107018.", "ArticleIdList": ["10.4236/ojgas.2020.107018"]}, {"Citation": "Yang J-M, Shen T-W. A pharmacophore-based evolutionary approach for screening selective estrogen receptor modulators. Prot Struct Funct Bioinform. 2005;59:205\u2013220. doi: 10.1002/prot.20387.", "ArticleIdList": ["10.1002/prot.20387", "15726586"]}, {"Citation": "Zhang Y, Vermeulen NPE, Commandeur JNM (2017) Characterization of human cytochrome P450 mediated bioactivation of amodiaquine and its major metabolite N-desethylamodiaquine. Br J Clin Pharmacol [Internet]. Blackwell Publishing Ltd 83(3):572\u201383. Available at: /pmc/articles/PMC5306493/ [cited 2021 Mar 28]", "ArticleIdList": ["PMC5306493", "27718269"]}, {"Citation": "Zhang S, Qu C, Wang Y, Wang W, Ma Z, Peppelenbosch MP, et al. Conservation and variation of the hepatitis E virus ORF2 capsid protein. Gene Elsevier BV. 2018;675:157\u201364.", "ArticleIdList": ["30180962"]}, {"Citation": "Zheng Q, Jiang J, He M, Zheng Z, Yu H, Li T, et al. Viral neutralization by antibody-imposed physical disruption. Proc Natl Acad Sci USA. 2019;116(52):26933\u201326940. doi: 10.1073/pnas.1916028116.", "ArticleIdList": ["10.1073/pnas.1916028116", "PMC6936700", "31818956"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "12", "Day": "28"}, {"Year": "2021", "Month": "4", "Day": "16"}, {"Year": "2021", "Month": "5", "Day": "7", "Hour": "7", "Minute": "14"}, {"Year": "2021", "Month": "5", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "5", "Day": "8", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "5", "Day": "4"}], "PublicationStatus": "epublish", "ArticleIdList": ["33959472", "PMC8093904", "10.1007/s40203-021-00093-y", "93"]}}], "PubmedBookArticle": []}